Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors

Cancer research · Myelofibrosis

The review discusses how genetic abnormalities and disease characteristics may help guide treatment decisions and explains practical strategies for switching therapies safely while avoiding complications during treatment transitions.

This review highlights current definitions of myelofibrosis-associated anemia, including trial and prognostic thresholds, and outlines its incidence, clinical impact, and multifactorial pathophysiology. Therapeutic approaches reviewed include supportive options, differential anemia profiles of JAK inhibitors and emerging targeted strategies like TGF‑β ligand traps, hepcidin‐pathway modulation, novel agents and combination approaches.

Optimizing outcomes in myelofibrosis requires proactive transition management, early identification of treatment failure, phenotype‑guided therapeutic sequencing, and integration of molecular risk assessment to improve long‑term disease management and clinical outcomes.

Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.

Original source

Related signals